首页 我的
吴士文 三甲
吴士文 主任医师
北京301医院第三医学中心 神经内科

联合布洛芬与硝酸异山梨酯是治疗肌营养不良有效方法,急需要进行人体试验

 

    这里通过联合布洛芬与硝酸异山梨酯来对肌营养不良的动物进行药物治疗试验,取得了很好的疗效。且两者联合使用优于单一药物使用。既往这两种药物都是临床上常用的,副作用小的药物,应该值得在临床上尽快对于肌营养不良患者进行临床试验研究。北京301医院第三医学中心神经内科吴士文

Br J Pharmacol. 2010 Jul;160(6):1550-60.
Co-administration of ibuprofen and nitric oxide is an effective experimental therapy for muscular dystrophy, with immediate applicability to humans.

Sciorati C, Buono R, Azzoni E, Casati S, Ciuffreda P, D'Angelo G, Cattaneo D, Brunelli S, Clementi E.

San Raffaele Scientific Institute, Stem Cell Research Institute, Milan, Italy.
Abstract

Background and purpose: Current therapies for muscular dystrophy are based on corticosteroids. Significant side effects associated with these therapies have prompted several studies aimed at identifying possible alternative strategies. As inflammation and defects of nitric oxide (NO) generation are key pathogenic events in muscular dystrophies, we have studied the effects of combining the NO donor isosorbide dinitrate (ISDN) and the non-steroidal anti-inflammatory drug ibuprofen. Experimental approach: alpha-Sarcoglycan-null mice were treated for up to 8 months with ISDN (30 mg.kg(-1)) plus ibuprofen (50 mg.kg(-1)) administered daily in the diet. Effects of ISDN and ibuprofen alone were assessed in parallel. Drug effects on animal motility and muscle function, muscle damage, inflammatory infiltrates and cytokine levels, as well as muscle regeneration including assessment of endogenous stem cell pool, were measured at selected time points. Key results: Combination of ibuprofen and ISDN stimulated regeneration capacity, of myogenic precursor cells, reduced muscle necrotic damage and inflammation. Muscle function in terms of free voluntary movement and resistance to exercise was maintained throughout the time window analysed. The effects of ISDN and ibuprofen administered separately were transient and significantly lower than those induced by their combination. Conclusions and implications: Co-administration of NO and ibuprofen provided synergistic beneficial effects in a mouse model of muscular dystrophy, leading to an effective therapy. Our results open the possibility of immediate clinical testing of a combination of ISDN and ibuprofen in dystrophic patients, as both components are approved for use in humans, with a good safety profile.

真诚赞赏,手留余香
吴士文
吴士文 主任医师
北京301医院第三医学中心 神经内科
问医生 问医生 去挂号 去挂号
App 内打开